As a part of Spring Innovation Week in Lisbon, we are excited to share that Biocytogen will be attending LSX Europe. This event will follow after BIO-Europe Spring, forming a comprehensive meeting point across the life science innovation lifecycle. Join us in learning from industry leaders and discussing the key strategies shaping the future of biotech.
What is LSX World Congress Europe?
LSX Europe brings together biotech, medtech, and pharmatech leaders across three dedicated tracks, creating unique crossover opportunities and expanded investor access. With targeted networking and strong investor participation, it’s a high impact platform to secure capital, build collaborations, and stay ahead of emerging growth trends.
Event Overview
Date: March 25th - 26th, 2026
Venue: Lisbon Congress Centre, Praça das Indústrias 1, 1300-307 Lisboa, Portugal
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We can’t wait to see you in Lisbon, Portugal!
